A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

摘要: Pegylated liposomal doxorubicin (PLD) is active in metastatic breast cancer. This observational study evaluated the efficacy and safety of PLD patients treated during routine clinical practice. Eligible had cancer were with according to dose schedule determined by their physician as part The primary objectives analyze toxicity therapy. 125 assessable. Median age was 62 years, 78% performance status 0-1, 60% estrogen-receptor-positive disease. treatment second- or third-line 69% patients. Prior anthracyclines (adjuvant metastatic) been used 56% majority (79%) received every 4 weeks at a median 40 mg/m2. Overall response rate 43% all 34% those previously anthracyclines. most common grade 3/4 adverse events skin toxicity/hand-foot syndrome (6%), leukopenia (3%). supports activity tolerability demonstrated trials.